Evaluation of Fluorescence-image Guided Wound Assessment vs. Standard Practice
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02315092|
Recruitment Status : Completed
First Posted : December 11, 2014
Last Update Posted : February 13, 2018
|Condition or disease||Intervention/treatment|
|Foot Ulcer, Diabetic Bacteria||Device: Fluorescence Imaging|
Chronic wounds and their associated care are a burden to patients and health care systems worldwide. Microbiological testing of wound samples is often used to identify and quantify bacterial species, the latter of which may be both an objective quantitative indicator of infection and a predictive correlate of healing. Microbiology reports contain useful information about microbial identities, antibiotic susceptibility, and semi-quantitative bacterial growth rates, but these data typically represent the bacterial load in the wound centre only, and often arrive 3-5 days later. There is an unmet clinical need to improve the microbiological sampling and treatment of wound infections. To address this need, we developed a handheld portable imaging device that obtains white light (WL) and fluorescence (FL) images (or video) of normal skin and wounds in high-resolution and in real-time, which can be used at the point-of-care. It was demonstrated in previous studies that the device1) provides image-guidance for tissue sampling, detecting clinically-significant levels of pathogenic bacteria and wound infection otherwise overlooked by conventional sampling and 2) provides image-guidance for wound treatment, accelerating wound closure compared with conventional therapies and quantitatively tracking long-term changes in bacterial bioburden and distribution in wounds.
The current trial aims to compare the assessment of diabetic foot ulcers by fluorescence image guidance to standard practice. The device will be used to acquire fluorescence images of diabetic foot ulcers: when wounds are illuminated by violet/blue light, most pathogenic bacterial species emit a unique red fluorescence signal. The device is intended to be used as part of the clinical assessment process, which may include visual assessment, signs of heat or high temperature, the presence of exudate, and redness in the area. Images will guide the clinician to inspect, sample or further evaluate areas where fluorescing bacteria is present. This study will allow us to determine the benefit of fluorescence image-guided procedure as compared to standard clinical practice to assess bacterial burden in diabetic foot ulcers. Microbiological swabbing under standard practice and fluoresce-guided imaging will be performed in order to compare the two techniques.
|Study Type :||Observational|
|Actual Enrollment :||80 participants|
|Official Title:||Evaluation of Fluorescence-image Guided Wound Assessment vs. Standard Practice|
|Study Start Date :||December 2014|
|Actual Primary Completion Date :||January 2017|
|Actual Study Completion Date :||January 2017|
Diabetic foot ulcers
Patients who present with diabetic foot ulcers will undergo fluorescence imaging.
Device: Fluorescence Imaging
Wounds will be imaged using violet light (405 nm) illumination to locate areas with bacterial presence to guide swabbing.
- Correlation of localized fluorescence signals in acquired images with microbiological samples [ Time Frame: At study visit (only one study visit) ]Microbiological swabs will be taking from fluorescence positive regions to correlate with bacterial presence
- Comparison of number/variety of bacteria obtained by fluorescence-guided sampling vs. standard practice [ Time Frame: At study visit (only one study visit) ]Microbiological swabs will be taking from the wound using standard practice and following fluorescence-image guidance
- Assessment of the clinical functionality of the K2 Imaging Device [ Time Frame: At study visit (only one study visit) ]Users feedback
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02315092
|Judy Dan Research and Treatment Centre|
|Toronto, Ontario, Canada, M2R1N5|
|Principal Investigator:||Ralph S DaCosta, PhD||Princess Margaret Cancer Centre, University Health Network|